Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.

作者： RD Rubens , , SB Kaye , M Soukop , CJ Williams

DOI: 10.1038/BJC.1991.488

关键词:

摘要: Fourteen patients with advanced breast cancer were treated the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for more effective use of this agent are discussed.